Wall Street analysts forecast that Dynavax Technologies Co. (NASDAQ:DVAX) will report earnings per share (EPS) of $0.05 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Dynavax Technologies’ earnings, with the lowest EPS estimate coming in at ($0.18) and the highest estimate coming in at $0.29. Dynavax Technologies posted earnings of ($0.15) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 133.3%. The firm is scheduled to report its next earnings results on Thursday, November 4th.
According to Zacks, analysts expect that Dynavax Technologies will report full year earnings of $0.51 per share for the current year, with EPS estimates ranging from $0.25 to $0.68. For the next fiscal year, analysts anticipate that the company will report earnings of $0.33 per share, with EPS estimates ranging from ($0.20) to $0.98. Zacks’ EPS averages are an average based on a survey of research analysts that follow Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Wednesday, August 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.06. Dynavax Technologies had a negative net margin of 3.37% and a negative return on equity of 7.33%. The company had revenue of $52.77 million during the quarter, compared to analysts’ expectations of $44.04 million.
Shares of DVAX stock opened at $14.44 on Tuesday. The company has a quick ratio of 2.43, a current ratio of 2.85 and a debt-to-equity ratio of 2.64. Dynavax Technologies has a 52 week low of $3.58 and a 52 week high of $20.40. The stock has a market capitalization of $1.66 billion, a PE ratio of -55.54 and a beta of 1.37. The firm has a 50 day moving average of $12.82 and a two-hundred day moving average of $10.48.
In other Dynavax Technologies news, SVP Robert Janssen sold 80,000 shares of the firm’s stock in a transaction on Friday, August 6th. The shares were sold at an average price of $10.75, for a total transaction of $860,000.00. Following the transaction, the senior vice president now directly owns 6,861 shares of the company’s stock, valued at approximately $73,755.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Andrew A. F. Hack sold 2,250,000 shares of the firm’s stock in a transaction on Monday, August 9th. The stock was sold at an average price of $10.80, for a total transaction of $24,300,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 4,408,268 shares of company stock worth $58,580,545 over the last quarter. 11.77% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Dynavax Technologies by 1.6% in the second quarter. The Manufacturers Life Insurance Company now owns 60,739 shares of the biopharmaceutical company’s stock valued at $598,000 after acquiring an additional 982 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of Dynavax Technologies by 6.7% in the second quarter. Arizona State Retirement System now owns 30,786 shares of the biopharmaceutical company’s stock valued at $303,000 after acquiring an additional 1,922 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in Dynavax Technologies by 17.7% during the second quarter. Teacher Retirement System of Texas now owns 12,912 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,942 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Dynavax Technologies by 4.6% during the second quarter. JPMorgan Chase & Co. now owns 65,754 shares of the biopharmaceutical company’s stock worth $648,000 after buying an additional 2,890 shares in the last quarter. Finally, Citigroup Inc. boosted its holdings in Dynavax Technologies by 0.7% during the second quarter. Citigroup Inc. now owns 433,929 shares of the biopharmaceutical company’s stock worth $4,274,000 after buying an additional 3,130 shares in the last quarter. 78.27% of the stock is currently owned by institutional investors and hedge funds.
Dynavax Technologies Company Profile
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.